BACKGROUND: Tyrosine kinase inhibitors (TKIs) improve the survival of patients with chronic myeloid leukemia (CML) dramatically; however, nonadherence to TKI therapy may lead to resistance to the therapy. TKIs are very expensive and are covered under Part D insurance for Medicare patients. To the authors' knowledge, the impact of low-income subsidy status and cost sharing on adherence among this group has not been well studied in the literature. METHODS: Surveillance, Epidemiology, and End Results (SEER) registry data linked with Medicare Part D data from the years 2007 through 2012 were used in the current study. The authors identified 836 patients with CML with Medicare Part D insurance coverage who were new TKI users. Treatment nonadherence was defined as a binary variable indicating the percentage of days covered was <80% during the 180-day period after the initiation of TKI therapy. Logistic regression was used to examine the relationship between out-of-pocket costs per 30-day drug supply, Medicare Part D plan characteristics, and treatment adherence while controlling for other patient characteristics. RESULTS: Overall, 244 of the 836 patients with CML (29%) were nonadherent to targeted oral therapy during the 180 days after the initiation of treatment with TKIs. The multivariable logistic regression demonstrated that patients with heavily subsidized (odds ratio, 6.7; 95% confidence interval, 2.8-15.9) and moderately subsidized (odds ratio, 3.0; 95% confidence interval, 1.4-6.5) Medicare Part D plans were much more likely to demonstrate nonadherence compared with patients without a subsidy. CONCLUSIONS: The current population-based study found a significantly higher rate of nonadherence among heavily subsidized patients with substantially lower out-of-pocket costs, which suggests that future research is needed to help lower the nonadherence rate among these individuals. Cancer 2018;124:364-73.
INTRODUCTION
There have been rapid developments in targeted oral therapies for cancer in the past decade. 1 For some cancer types, targeted oral anticancer drugs have become the standard of care. One example is how a group of tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib, and nilotinib, have transformed the treatment of patients with chronic myeloid leukemia (CML). The survival of patients with CML has improved dramatically due to the use of these TKIs. 2, 3 However, loss of response (resistance) to TKI therapy remains a significant challenge in the treatment of CML and results in fewer treatment options and worse clinical outcomes. 4 Researchers have found that poor adherence to TKI therapy is strongly associated with loss of response and treatment failure. 5, 6 Oral TKIs are very expensive, and constitute a major contributing factor to the rapid rise in chemotherapy costs in the United States. 7 The financial burden of TKI treatment and the negative impact of nonadherence has raised many concerns that patient nonadherence, which is strongly influenced by high drug costs, may lead to undesired clinical and economic outcomes.
Studies have found that nonadherence to TKI treatment results in lower pharmacy costs but much higher medical costs and higher total costs overall. [8] [9] [10] To our knowledge, there are many articles in the literature demonstrating that higher cost burdens on patients can lead to worse adherence to medications. [11] [12] [13] [14] One important study regarding the relationship between cost sharing and adherence to TKIs found that higher copayments were significantly associated with nonadherence. 15 However, to the best of our knowledge, the majority of these studies were based on employer-sponsored insurance and the main study populations were younger patients. CML is most frequently diagnosed among individuals aged 65 to 74 years; approximately one-half of newly diagnosed patients are aged 65 years. 16 Given the higher incidence of the disease among the elderly population, it is important to investigate the relationship between adherence and drug cost sharing for elderly patients with CML, who most likely have Medicare Part D prescription plans.
The Medicare Part D prescription drug benefit began in 2006 as an important component of Medicare insurance. Under Medicare Part D, some beneficiaries receive the low-income subsidy (LIS) and receive assistance in paying for Medicare Part D prescription drug costs; they also do not experience a gap in prescription drug coverage. Eligibility and the amount of the subsidy depend on the individual's income compared with the federal poverty level and resource limitations. In 2014, >11 million Medicare Part D enrollees received the LIS. 17 There have been many studies examining the relationship between LIS and medication adherence. One article found that adherence to diabetes medication was moderately better among LIS beneficiaries compared with beneficiaries without subsidies. 18 Another study focused on patient adherence to treatment with clopidogrel after stent placement and found that beneficiaries with LIS had better adherence. 19 However, to the best of our knowledge, there is scarce literature regarding patients with CML covered under Medicare Part D prescription plans who are being treated with expensive oral TKI therapies. Studies have shown that although higher cost sharing generally is associated with reductions in specialty drug use, the effects varied significantly by type of disease and specialty drug. 20 There are 2 important recent studies 21, 22 that have examined TKI use among Medicare beneficiaries with CML. Both studies focused mainly on the initiation of TKI therapy among patients newly diagnosed with CML and both found that patients with the LIS were more likely to initiate TKI treatment. It is interesting to note that that the second study 22 found that despite the differences in initiation between patients with and without subsidies, once the treatment was initiated there was no significant difference noted with regard to adherence between patients with and without subsidies. It is possible that this conclusion is due in part to the small sample size of the study, because the analysis on adherence was based on 202 patients with stand-alone Medicare Part D plans. In contrast to these 2 studies on newly diagnosed patients, the current study focused on the adherence to TKI therapy among a larger group of patients with prevalent CML (836 patients) who initiated TKI therapy with a 6-month washout period. The current study sample included both patients with stand-alone Medicare Part D plans and patients with other Medicare Part D plans such as managed care organization (MCO), regional preferred provider organization (RPPO), and employer-sponsored plans. Furthermore, we calculated the actual patient outof-pocket (OOP) payment per 30-day supply of TKIs and also considered their OOP payments for other drugs. The objective of the current study was to examine the relationship between cost sharing, Medicare Part D plan type, LIS status, and adherence to oral TKI treatment among elderly patients with CML who initiated TKI therapy and had Medicare Part D prescription plans.
MATERIALS AND METHODS

Data Source
In the current study, we used the Surveillance, Epidemiology, and End Results (SEER) registry data linked with Medicare Part D data from 2007 to 2012 (the newest data available at the time of the study). The SEER registries of the National Cancer Institute are a large data source providing information regarding cancer incidence and characteristics covering approximately 28% of the US population. The linkage to Medicare Part D data enhances the information that is available by providing details concerning patient demographics, prescription drug plans, and drug use.
Study Cohort
We first selected patients diagnosed with CML on or before 2012 based on the SEER registry cancer site information according to the World Health Organization classification for hematopoietic and lymphoid tissue tumors (ie, International Classification of Diseases for Oncology, Third Edition [ICD-O-3] codes 9863, 9875-9876, and 9945-9946). 23 We then identified new users of any of the 3 TKIs that we studied (imatinib, dasatinib, and nilotinib) by imposing a washout period of at least 6 months without any use of the above TKIs. To ensure complete Medicare claims to capture their prescription drug use, we restricted the sample to include patients with continuous enrollment in one type of prescription plan (either a traditional stand-alone Medicare Part D plan, regional PPO plan, MCOs other than an RPPO, or an employersponsored plan throughout) during the 6 months before and 6 months after the initiation of TKI therapy. We further required that the patients' prescription plans and subsidy and copayment status did not change throughout this time period. Finally, we excluded those patients with missing demographic information. The final study cohort included 836 patients for analysis. The detailed inclusion Adherence to Tyrosine Kinase Inhibitors/Shen et al Cancer and exclusion steps of this study cohort are provided in Table 1 .
Key Variables
We examined nonadherence to TKI therapy during the 6 months after the start of therapy. We defined nonadherence as a binary variable indicating that the percentage of days covered was <80%. 24 In other words, patients were considered to be nonadherent if the number of days of the TKI supply covered <80% of days for the patient during the 180-day period after the initiation of TKI therapy. We did not exclude hospitalization days because TKIs are very expensive and hospitals are unlikely to include them on the hospital formularies. 25 The 4 key independent variables were the OOP cost per 30-day supply of TKIs, OOP cost spent on other drugs during the 180 days, Medicare Part D plan subsidy status, and Medicare Part D plan type. We divided the total OOP payments for TKIs by the total days of drug supply during the 180-day period after treatment initiation and then multiplied it by 30 to obtain the OOP cost per 30-day supply. All costs were adjusted for inflation to 2014 US dollars based on the medical care component of the Consumer Price Index.
We created 3 groups for subsidy status: 1) heavily subsidized (100% premium subsidy with no or low copayment); 2) moderately subsidized (some premium subsidy and copayment); and 3) no subsidy. The Medicare Part D plan types were categorized into 2 groups: 1) traditional stand-alone Medicare Part D plans; and 2) all other plans, including MCOs, RPPOs, and employersponsored plans. MCOs and RPPOs are networks of health care providers who offer managed care health plans. MCOs usually pay only for health services within this network. RPPOs pay for services within and outside of the network, with the patients paying a higher percentage of cost sharing when out-of-network services were used.
Employer-sponsored plans are group insurance plans offered by employers. The employers negotiate with insurers and often provide a range of plan options to employees.
Other Independent Variables
We included patients' demographic information, neighborhood socioeconomic status, and the year when they initiated therapy with TKIs. The demographic characteristics included age (70 years vs >70 years), sex (male vs female), race (white vs nonwhite), region (Northeast, West, Midwest, or South), and urban/rural status (metropolitan vs nonmetropolitan). The neighborhood socioeconomic status variables included 3 variables in terms of quartiles: median household income, percentage living in poverty, and percentage with at least 4 years of college education. It should be noted that the quartile cutoff values change every year, and we provide the cutoff levels in Supporting Information Table 1 .
Statistical Analyses
We provided descriptive statistics of the current study cohort. Group differences in nonadherence to TKI therapy were tested with chi-square statistics. For the continuous variables of OOP cost per 30-day TKI supply and OOP payment for all other drugs, the Wilcoxon-MannWhitney test was used to test the difference because the cost variable is skewed. We also provided the box plots of OOP costs per 30-day supply of TKIs by subsidy status. We used a multivariate logistic regression to explore factors associated with nonadherence to TKIs, and presented the findings as adjusted odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs). Because patients with subsidies and patients without subsidies are likely to be 2 very different groups and respond to factors differently, we also conducted subgroup analyses for these 2 groups. All statistical analyses were conducted using SAS statistical software (version 9.3; SAS Institute Inc, Abbreviations: CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.
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Cary, North Carolina). This study received exemption status from the institutional review board at The University of Texas MD Anderson Cancer Center in Houston. Table 2 provides detailed descriptive statistics of the study cohort. Overall, 244 of the 836 patients with CML (29%) were found to be nonadherent to TKIs during the 180 days after drug initiation. Patients with heavily subsidized plans were found to be significantly more likely to be nonadherent (P 5 .036). It is interesting to note that a much higher percentage of patients with heavily subsidized plans were nonadherent compared with patients with no subsidy (36% vs 27%, respectively), whereas patients with moderately subsidized plans demonstrated less nonadherence (25%). In terms of OOP cost per 30-day TKI supply, the nonadherent individuals had higher costs (mean, $829 vs $567; P 5 .005).
RESULTS
We also analyzed the OOP costs per 30-day TKI supply by subsidy status. The box plot (Fig. 1) shows the substantial difference in OOP costs for patients based on subsidy status. Patients who were heavily subsidized had very low OOP costs, with a median of $1.3 per 30-day supply of TKIs and an interquartile range of $1.3. The moderately subsidized group also had low OOP costs, with a median of $3.0 and an interquartile range of $3.6, whereas the group without a subsidy had much higher OOP costs, with a median of $980.7 and an interquartile range of $668.6. When taken together, the current study findings suggest that although patients who were heavily subsidized had low OOP costs, their drug adherence was worse than that of individuals in the moderately subsidized group or the group with no subsidy. Table 3 presents the results from the logistic regression for the whole cohort. Adjusted for all factors included in the model, the regression still demonstrated that the heavily subsidized group was much more likely to be nonadherent compared with the nonsubsidized group, with an adjusted OR of 6.69 (95% CI, 2.81-15.9). Moderately subsidized patients also were found to be more likely to demonstrate nonadherence (OR, 2.99; 95% CI, 1.38-6.46) compared with patients without a subsidy. Unsurprisingly, controlling for all other factors, patients with higher OOP payments per 30-day supply were more likely to have TKI medication nonadherence issues compared with individuals with lower OOP payments. The OR associated with a doubling of OOP costs per 30-day TKI supply was 1.12 (95% CI, 1.02-1.22); the corresponding OR for OOP costs for other drugs was 1.1 (95% CI, 1.01-1.19). None of the residence-related variables (ie, urban/rural status, region, and neighborhood socioeconomic status) were found to be significantly associated with nonadherence to TKI therapy. Table 3 also includes results when the model excluded the OOP cost variables. After excluding the 2 cost variables, the magnitude of association between having a heavy subsidy and nonadherence was reduced significantly (OR, 1.7; 95% CI, 1.13-2.55), and the association between having a moderate subsidy and nonadherence became insignificant. Table 4 presents the subgroup analyses for patients with and without subsidies using a multivariable logistic model. The analyses demonstrated different effects of various factors in these 2 subgroups. For example, in the subgroup without subsidies, older patients (those aged >70 years vs those aged 70 years) were more likely to be nonadherent (OR, 1.86; 95% CI, 1.2-2.88), whereas in the subgroup with subsidies, older patients had an OR of 0.86, albeit statistically insignificant. In the subgroup without subsidies, having a Medicare prescription drug plan was found to be significantly associated with a lower likelihood of nonadherence (OR, 0.63; 95% CI, 0.4-0.99); in the subgroup with subsidies, the association was opposite, albeit statistically insignificant. 
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Even among patients with subsidies, patients with heavily subsidized plans were much more likely (OR, 3.51; 95% CI, 1.73-7.13) to be nonadherent compared with those with moderately subsidized plans. Higher OOP costs (ie, a doubling of the costs) per 30-day TKI supply, even within the subgroup with subsidies, were associated with a higher likelihood of nonadherence (OR, 1.32; 95% CI, 1.08-1.62); the corresponding OR Abbreviations: 95% CI, 95% confidence interval; NA, not applicable; OR, odds ratio; PDP, prescription drug plan; PPO, preferred provider organization; TKI, tyrosine kinase inhibitor.
We also examined the percentage of patients having a predicted probability of nonadherence to TKI therapy that was >50% (ie, those more likely to be nonadherent than not) based on the results of these subgroup analyses. The models predicted that the percentage of patients who are more likely to be nonadherent than not is 5% (in the group without a subsidy) versus 15% (in the group with a subsidy); this large difference further confirms the importance of subsidy status on adherence to TKI therapy.
DISCUSSION
Using SEER registry data linked with Medicare Part D claims from 2007 through 2012, we examined the relationship between patient cost sharing, subsidy status, and nonadherence to targeted oral therapies among patients with CML. We found that the OOP cost per 30-day supply of TKIs was a strong predictor of nonadherence to TKI therapy. Patients with higher OOP costs were much more likely to have nonadherence issues. This finding has important implications because nonadherence to oral TKIs may lead to severe consequences from both a clinical and economic perspective. [4] [5] [6] [8] [9] [10] These findings are consistent with the body of literature regarding adherence to TKIs and OOP costs. In particular, another study 15 based on patients with CML who were covered by private insurance also found that patients with higher copayments were more likely to be nonadherent. However, patients covered by private insurance and patients with Medicare Part D plans have different characteristics. Patients covered by Medicare are older and Medicare Part D plans usually require both copayment and coinsurance rather than copayment alone, and OOP costs are higher because of the high price of the TKI drugs. Indeed, we found that patients with CML in the current study who were covered by Medicare Part D had much higher OOP costs for a 30-day supply of TKIs and the nonadherence rate also was much higher. More specifically, the median OOP cost for a 30-day supply was $452 in the current study cohort compared with the $30 median copayment for the privately insured patients in the previous study 15 ; the corresponding nonadherence rates were 29% compared with 23%, respectively. Furthermore, after controlling for OOP costs and other patient characteristics, we found that Medicare Part D beneficiaries with subsidies were much more likely to be nonadherent. Given the eligibility criteria for subsidies, the patients with subsidies had lower income and fewer economic resources. Many studies of different patient populations have shown that lower income and fewer economic resources are significantly associated with worse medication adherence. One systematic review 26 among patients with breast cancer demonstrated that lower socioeconomic status was significantly associated with lower adherence to endocrine therapy. A Brazilian single-center study of patients with CML found better adherence to TKIs among patients of higher socioeconomic status. 27 A recent study by Winn et al focusing on TKI initiation within 180 days after a diagnosis of CML and subsequent TKI therapy adherence found an insignificant difference in adherence rates based on subsidy status; instead, higher initiation rates were identified for individuals with costsharing subsidies. 22 In stark contrast, the results of the current study demonstrate that despite substantially lower OOP costs for patients with LIS status, this population still had difficulty adhering to treatment with TKIs. It is possible that the discrepancy in the current study findings is due to the inclusion of OOP costs in our analyses, which separated out the impact of the subsidy on OOP costs. Indeed, we found that if we excluded the OOP cost variables, the association between subsidy status and nonadherence was lowered significantly. Another explanation is the bigger sample size in the current study focusing on patients who had initiated TKI therapy, resulting in 836 patients herein compared with 202 in the study by Winn et al. 22 To the best of our knowledge, there is vast published literature regarding the various factors related to nonadherence to oral anticancer medications. 28, 29 One article concerning adherence to oral TKIs among patients with CML demonstrated that there is a complex interplay of factors that influence adherence, including clinical benefits, side effects, economic burden, functional status, patient knowledge and beliefs, physician interactions, lifestyle factors, behavioral management, and family support. 30 Another study of patients with CML performed in Italy found that social support, satisfaction with the information received, and concomitant drug burden had a significant impact on adherence to imatinib therapy. 31 Some studies have shown that there can be associations between the number of physician visits and adherence to oral anticancer medications. Although more follow-up visits may help to improve adherence, 32, 33 nonadherence may lead to higher numbers of physician visits. 34, 35 To examine the association between the number of physician visits and nonadherence among patients, we identified a subgroup of patients who had continuous Medicare Parts A and B enrollment and no health management organization enrollment during the 6 months after TKI initiation to ensure completeness of medical claims. For this subgroup, we calculated the number of outpatient visits during the 6 months based on the medical claims. We found no statistically significant difference in adherence (P value 5 .75, Student t test). Of the 529 patients in this subgroup, 375 were adherent to TKI treatment, whereas 154 were nonadherent. The mean number of visits was 22.79 and 23.16, respectively, for the adherent and nonadherent groups, and standard deviations were 11.89 versus 12.14, respectively. Therefore, it is likely that many of these other factors such as social support, health literacy, patient mental conditions, and relationship with the oncologist played a more prominent role in the higher nonadherence noted among patients who received the LIS. For example, some of these patients may have had worse functional status, inadequate knowledge about the adverse impact of nonadherence to TKI therapy, less-than-satisfactory physician interactions, poor behavior management, and little family support. The fact that the lower OOP costs did not completely mediate the impact of lower socioeconomic status on nonadherence suggests that future strategies to promote better adherence to oral TKIs and reduce socioeconomic disparities should consider many dimensions other than reducing the OOP cost burden on patients. Studies have shown that educational, behavioral, affective, and multidimensional interventions improve adherence to medications. 28, 36 Focus group studies or surveys and interventional studies improving social support and patient education among patients with CML would be interesting directions for future research.
The current study is based on SEER registry data linked with Medicare Part D claims, and therefore was constrained by the availability and accuracy of the information available in the registry and claims data. For example, some of the adverse side effects of TKIs, such as rash and headache, are difficult to capture in claims data. Therefore, we were not able to assess the impact of adverse effects on adherence. If patients received free TKIs through patient assistance programs, it would not be captured in the Medicare insurance claims. There are many charity foundations that help patients receive anticancer medications. [37] [38] [39] Therefore, the adherence rate may be underestimated. Because the health care system in the United States is different from that of the rest of world, some of the results in the current study may not apply to other countries. However, one major finding of this study is that patients with CML with less financial means still have much lower adherence even when they are heavily subsidized (and hence have very low OOP costs for TKIs). Such a finding should have relevance for other countries, even if they have universal health coverage and relatively low OOP costs. Nevertheless, to the best of our knowledge, the current study is the first in the literature to examine the impact of cost sharing on drug adherence among patients with CML who are covered under Medicare Part D plans. We confirmed the impact of OOP costs on adherence, and found that patients with subsidies had much worse adherence. The results of the current study demonstrate the urgent need to find ways in which adherence to TKIs, an important drug class that is a first-line treatment of patients with CML, can be improved among low-income patients with limited economic resources.
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